RT Journal Article
T1 An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times
A1 García Montero, Cielo
A1 Fraile Martínez, Oscar
A1 Bravo Arribas, Coral
A1 Torres Carranza, Diego
A1 Sanchez Trujillo, Lara
A1 Gómez Lahoz, Ana M.
A1 Guijarro, Luis G.
A1 García Honduvilla, Natalio
A1 Asúnsolo, Angel
A1 Bujan, Julia
A1 Monserrat, Jorge
A1 Serrano, Encarnación
A1 Álvarez Mon, Melchor
A1 De León Luis, Juan Antonio
A1 Alvarez Mon, Miguel Ángel
A1 Ortega, Miguel A.
AB Since the worldwide COVID-19 pandemic was declared a year ago, the search for vaccines has become the top priority in order to restore normalcy after 2.5 million deaths worldwide, overloaded sanitary systems, and a huge economic burden. Vaccine development has represented a step towards the desired herd immunity in a short period of time, owing to a high level of investment, the focus of researchers, and the urge for the authorization of the faster administration of vaccines. Nevertheless, this objective may only be achieved by pursuing effective strategies and policies in various countries worldwide. In the present review, some aspects involved in accomplishing a successful vaccination program are addressed, in addition to the importance of vaccination in a pandemic in the face of unwillingness, conspiracy theories, or a lack of information among the public. Moreover, we provide some updated points related to the landscape of the clinical development of vaccine candidates, specifically, the top five vaccines that are already being assessed in Phase IV clinical trials (BNT162b2, mRNA-1273, AZD1222, Ad26.COV2.S, and CoronaVac).
PB MDPI
SN 2076-393X
YR 2021
FD 2021-04-27
LK https://hdl.handle.net/20.500.14352/7399
UL https://hdl.handle.net/20.500.14352/7399
LA eng
NO García-Montero C, Fraile-Martínez O, Bravo C, Torres-Carranza D, Sanchez-Trujillo L, Gómez-Lahoz AM, et al. An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times. Vaccines 2021;9:433. https://doi.org/10.3390/vaccines9050433.
NO This work was partially supported by grants from the Fondo de Investigación de la Seguridad Social, Instituto de Salud Carlos III (PI18/00912), Spain; Programa de Actividades de I+D de la Comunidad de Madrid en Biomedicina (B2017/BMD3804), Madrid, Spain; and Instituto de Salud Carlos III CIBER Enfermedades hepáticas y Digestivas, Spain.
NO Comunidad de Madrid
NO Instituto de Salud Carlos III
DS Docta Complutense
RD 16 dic 2025